COBRA-Reduce – Cobra PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated with Oral Anticoagulation Undergoing Percutaneous Coronary Intervention

CONDUCT – Edwards SAPIEN 3 PPI retrospective Registry

TOMAHAWK – Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation

ATTICUS Amendment B – Apixaban for treatment of embolic stroke of undetermined source

AUGUSTUS – An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety ofApixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and AcuteCoronary Syndrome or Percutaneous Coronary Intervention

ELIMINATE-AF – A PROSPECTIVE, RANDOMIZED, OPEN-LABEL,BLINDED ENDPOINT EVALUATION (PROBE)PARALLEL GROUP STUDY COMPARING EDOXABANVS. VKA IN SUBJECTS UNDERGOING CATHETERABLATION OF NON-VALVULAR ATRIALFIBRILLATION (ELIMINATE-AF)

EMIT-AF/VTE – Edoxaban management in diagnostic and therapeutic procedures

ENTRUST-AF-PCI – Evaluation of the safety and efficacy of an edoxaban-basedcompared to a vitamin K antagonist-based antithrombotic regimenfollowing successful percutaneous coronary intervention (PCI)with stent placement. (EdoxabaN Treatment versus VKA inpatients with AF undergoing PCI)

ProgressPVL Registry – Prospektive Beobachtung derAortenklappeninsuffizienz nach TAVI und derweitere Verlauf

Atticus – Apixaban for treatment of embolic Stroke

EA-V – EuroAspire V

EARTH-TAVR – EvAluation of ceRebral THromboembolism after TAVR (EARTH TAVR)

ETNA-VTE-Europe – Non-Interventional Study on Edoxaban Treatmentin Routine Clinical Practice in Patientswith Venous Thromboembolism in Europe

Relax-AHF-EU – A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart faiure (AHF) patients

ATTICUS – Apixaban for treatment of embolic stroke of undetermined source

REVEAL-ACS – IIR, VDO031 (D1BVXAL02800), Geisler

TWIGHLIGHT Study – Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention